SVB Securities raised the firm’s price target on Reata Pharmaceuticals to $75 from $35 and keeps a Market Perform rating on the shares. With the saga finally coming to a close, the FDA acquiesced and granted Skyclarys approval in Friedreich’s ataxia/FA, which comes as a bit of a surprise, given the agency’s past concerns, the firm notes.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RETA:
- Reata Pharmaceuticals price target raised to $105 from $75 at Stifel
- Reata Skyrockets on FDA Approval for Friedreich’s Ataxia Drug
- Reata Pharmaceuticals price target raised to $85 from $40 at Baird
- Reata Pharmaceuticals price target raised to $121 from $61 at Cantor Fitzgerald
- Reata Pharmaceuticals price target raised to $120 from $53 at Citi
